STOCK TITAN

[Form 4] Vivani Medical, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Director Daniel Bradbury reported two key transactions in Vivani Medical (VANI) stock options:

  • Acquired 35,135 non-qualified stock options on June 24, 2025, with exercise price of $1.27. These options vest fully on either the first anniversary or next annual stockholder meeting, whichever comes first. This was part of the annual director compensation policy.
  • Correction to previous grant from January 1, 2025: Total options adjusted down from 50,059 to 49,822 (reduction of 237) due to clerical error. These options have a $1.16 exercise price and vest quarterly.

The transactions reflect standard board compensation practices and administrative corrections rather than open market trading activity. All holdings are directly owned, with no indirect beneficial ownership reported.

Il direttore Daniel Bradbury ha comunicato due operazioni chiave relative alle opzioni su azioni di Vivani Medical (VANI):

  • Ha acquisito 35.135 opzioni su azioni non qualificate il 24 giugno 2025, con un prezzo di esercizio di 1,27 $. Queste opzioni maturano completamente al primo anniversario o alla successiva assemblea annuale degli azionisti, a seconda di quale evento si verifichi prima. Si tratta di una componente della politica di compenso annuale per i direttori.
  • Correzione di una concessione precedente del 1° gennaio 2025: il numero totale di opzioni è stato ridotto da 50.059 a 49.822 (una diminuzione di 237) a causa di un errore amministrativo. Queste opzioni hanno un prezzo di esercizio di 1,16 $ e maturano trimestralmente.

Le operazioni riflettono prassi standard di compensazione del consiglio e correzioni amministrative, non attività di trading sul mercato aperto. Tutte le partecipazioni sono detenute direttamente, senza alcuna proprietà indiretta segnalata.

El director Daniel Bradbury informó sobre dos transacciones clave relacionadas con opciones sobre acciones de Vivani Medical (VANI):

  • Adquirió 35,135 opciones sobre acciones no calificadas el 24 de junio de 2025, con un precio de ejercicio de $1.27. Estas opciones se consolidan completamente en el primer aniversario o en la próxima junta anual de accionistas, lo que ocurra primero. Esto forma parte de la política anual de compensación para directores.
  • Corrección a la concesión previa del 1 de enero de 2025: el total de opciones fue ajustado a la baja de 50,059 a 49,822 (reducción de 237) debido a un error administrativo. Estas opciones tienen un precio de ejercicio de $1.16 y se consolidan trimestralmente.

Las transacciones reflejan prácticas estándar de compensación del consejo y correcciones administrativas, no actividad de negociación en el mercado abierto. Todas las participaciones son de propiedad directa, sin reportes de propiedad indirecta.

이사 다니엘 브래드버리는 Vivani Medical(VANI) 주식 옵션과 관련된 두 가지 주요 거래를 보고했습니다:

  • 2025년 6월 24일에 35,135개의 비자격 주식 옵션을 취득했으며, 행사가격은 $1.27입니다. 이 옵션들은 첫 번째 기념일 또는 다음 연례 주주총회 중 먼저 도래하는 시점에 전액 베스팅됩니다. 이는 연간 이사 보상 정책의 일부입니다.
  • 2025년 1월 1일 이전 부여에 대한 정정: 총 옵션 수가 50,059개에서 49,822개(237개 감소)로 행정 실수로 조정되었습니다. 이 옵션들은 행사가격 $1.16이며 분기별로 베스팅됩니다.

이 거래들은 공개 시장 거래 활동이 아닌 이사회 보상 관행 및 행정적 정정을 반영합니다. 모든 보유 주식은 직접 소유되었으며 간접적인 실질 소유 보고는 없습니다.

Le directeur Daniel Bradbury a signalé deux transactions clés concernant les options d'achat d'actions de Vivani Medical (VANI) :

  • Acquisition de 35 135 options d'achat d'actions non qualifiées le 24 juin 2025, au prix d'exercice de 1,27 $. Ces options deviennent entièrement acquises soit à la première date anniversaire, soit à la prochaine assemblée annuelle des actionnaires, selon la première échéance. Cela fait partie de la politique annuelle de rémunération des administrateurs.
  • Correction d'une attribution précédente du 1er janvier 2025 : le nombre total d'options a été ajusté à la baisse, passant de 50 059 à 49 822 (réduction de 237) en raison d'une erreur administrative. Ces options ont un prix d'exercice de 1,16 $ et sont acquises trimestriellement.

Ces transactions reflètent des pratiques standard de rémunération du conseil d'administration et des corrections administratives, plutôt qu'une activité de négociation sur le marché libre. Toutes les participations sont détenues directement, sans déclaration de propriété indirecte.

Direktor Daniel Bradbury meldete zwei wichtige Transaktionen bezüglich der Aktienoptionen von Vivani Medical (VANI):

  • Am 24. Juni 2025 wurden 35.135 nicht qualifizierte Aktienoptionen zu einem Ausübungspreis von 1,27 $ erworben. Diese Optionen werden vollständig entweder am ersten Jahrestag oder bei der nächsten jährlichen Hauptversammlung der Aktionäre fällig, je nachdem, welches Ereignis zuerst eintritt. Dies ist Teil der jährlichen Vergütungspolitik für Direktoren.
  • Korrektur einer vorherigen Zuteilung vom 1. Januar 2025: Die Gesamtzahl der Optionen wurde aufgrund eines Verwaltungsfehlers von 50.059 auf 49.822 (Reduktion um 237) angepasst. Diese Optionen haben einen Ausübungspreis von 1,16 $ und werden vierteljährlich fällig.

Die Transaktionen spiegeln übliche Vergütungspraktiken des Vorstands und administrative Korrekturen wider, keine Handelsaktivitäten am offenen Markt. Alle Beteiligungen sind direkt gehalten, es wurden keine indirekten wirtschaftlichen Eigentumsrechte gemeldet.

Positive
  • None.
Negative
  • None.

Il direttore Daniel Bradbury ha comunicato due operazioni chiave relative alle opzioni su azioni di Vivani Medical (VANI):

  • Ha acquisito 35.135 opzioni su azioni non qualificate il 24 giugno 2025, con un prezzo di esercizio di 1,27 $. Queste opzioni maturano completamente al primo anniversario o alla successiva assemblea annuale degli azionisti, a seconda di quale evento si verifichi prima. Si tratta di una componente della politica di compenso annuale per i direttori.
  • Correzione di una concessione precedente del 1° gennaio 2025: il numero totale di opzioni è stato ridotto da 50.059 a 49.822 (una diminuzione di 237) a causa di un errore amministrativo. Queste opzioni hanno un prezzo di esercizio di 1,16 $ e maturano trimestralmente.

Le operazioni riflettono prassi standard di compensazione del consiglio e correzioni amministrative, non attività di trading sul mercato aperto. Tutte le partecipazioni sono detenute direttamente, senza alcuna proprietà indiretta segnalata.

El director Daniel Bradbury informó sobre dos transacciones clave relacionadas con opciones sobre acciones de Vivani Medical (VANI):

  • Adquirió 35,135 opciones sobre acciones no calificadas el 24 de junio de 2025, con un precio de ejercicio de $1.27. Estas opciones se consolidan completamente en el primer aniversario o en la próxima junta anual de accionistas, lo que ocurra primero. Esto forma parte de la política anual de compensación para directores.
  • Corrección a la concesión previa del 1 de enero de 2025: el total de opciones fue ajustado a la baja de 50,059 a 49,822 (reducción de 237) debido a un error administrativo. Estas opciones tienen un precio de ejercicio de $1.16 y se consolidan trimestralmente.

Las transacciones reflejan prácticas estándar de compensación del consejo y correcciones administrativas, no actividad de negociación en el mercado abierto. Todas las participaciones son de propiedad directa, sin reportes de propiedad indirecta.

이사 다니엘 브래드버리는 Vivani Medical(VANI) 주식 옵션과 관련된 두 가지 주요 거래를 보고했습니다:

  • 2025년 6월 24일에 35,135개의 비자격 주식 옵션을 취득했으며, 행사가격은 $1.27입니다. 이 옵션들은 첫 번째 기념일 또는 다음 연례 주주총회 중 먼저 도래하는 시점에 전액 베스팅됩니다. 이는 연간 이사 보상 정책의 일부입니다.
  • 2025년 1월 1일 이전 부여에 대한 정정: 총 옵션 수가 50,059개에서 49,822개(237개 감소)로 행정 실수로 조정되었습니다. 이 옵션들은 행사가격 $1.16이며 분기별로 베스팅됩니다.

이 거래들은 공개 시장 거래 활동이 아닌 이사회 보상 관행 및 행정적 정정을 반영합니다. 모든 보유 주식은 직접 소유되었으며 간접적인 실질 소유 보고는 없습니다.

Le directeur Daniel Bradbury a signalé deux transactions clés concernant les options d'achat d'actions de Vivani Medical (VANI) :

  • Acquisition de 35 135 options d'achat d'actions non qualifiées le 24 juin 2025, au prix d'exercice de 1,27 $. Ces options deviennent entièrement acquises soit à la première date anniversaire, soit à la prochaine assemblée annuelle des actionnaires, selon la première échéance. Cela fait partie de la politique annuelle de rémunération des administrateurs.
  • Correction d'une attribution précédente du 1er janvier 2025 : le nombre total d'options a été ajusté à la baisse, passant de 50 059 à 49 822 (réduction de 237) en raison d'une erreur administrative. Ces options ont un prix d'exercice de 1,16 $ et sont acquises trimestriellement.

Ces transactions reflètent des pratiques standard de rémunération du conseil d'administration et des corrections administratives, plutôt qu'une activité de négociation sur le marché libre. Toutes les participations sont détenues directement, sans déclaration de propriété indirecte.

Direktor Daniel Bradbury meldete zwei wichtige Transaktionen bezüglich der Aktienoptionen von Vivani Medical (VANI):

  • Am 24. Juni 2025 wurden 35.135 nicht qualifizierte Aktienoptionen zu einem Ausübungspreis von 1,27 $ erworben. Diese Optionen werden vollständig entweder am ersten Jahrestag oder bei der nächsten jährlichen Hauptversammlung der Aktionäre fällig, je nachdem, welches Ereignis zuerst eintritt. Dies ist Teil der jährlichen Vergütungspolitik für Direktoren.
  • Korrektur einer vorherigen Zuteilung vom 1. Januar 2025: Die Gesamtzahl der Optionen wurde aufgrund eines Verwaltungsfehlers von 50.059 auf 49.822 (Reduktion um 237) angepasst. Diese Optionen haben einen Ausübungspreis von 1,16 $ und werden vierteljährlich fällig.

Die Transaktionen spiegeln übliche Vergütungspraktiken des Vorstands und administrative Korrekturen wider, keine Handelsaktivitäten am offenen Markt. Alle Beteiligungen sind direkt gehalten, es wurden keine indirekten wirtschaftlichen Eigentumsrechte gemeldet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BRADBURY DANIEL

(Last) (First) (Middle)
C/O VIVANI MEDICAL, INC.
1350 S. LOOP ROAD

(Street)
ALAMEDA CA 94502

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Vivani Medical, Inc. [ VANI ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Non-Qualified Stock Option (right to buy) $1.27 06/24/2025 A 35,135 (1)(2) 06/23/2035 Common Stock 35,135(2) $1.27(2) 35,135(2) D
Non-Qualified Stock Option (right to buy) $1.16 01/01/2025 D(3) 237(3) (4) 12/31/2034 Common Stock 237(3) $1.16 49,822(3) D
Explanation of Responses:
1. Annual grant awarded pursuant to the Issuer's Non-Employee Director Compensation Policy.
2. The option vests in total on the earlier of (i) the first anniversary of the grant or (ii) the next annual meeting of stockholders, subject to continued service through such date.
3. Reflects an adjustment to a previously reported amount grant on 01/01/2025 from 50,059 to 49,822 due to a clerical error.
4. The option will vest one-fourth at the end of each calendar quarter following the grant date, subject to continued service through each such date.
Remarks:
Exhibit 24 Power of Attorney
/s/ Adam Mendelsohn, Attorney-in-fact 06/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options did VANI director Daniel Bradbury receive on June 24, 2025?

Daniel Bradbury received 35,135 non-qualified stock options with an exercise price of $1.27 on June 24, 2025. These options were granted as part of VANI's annual Non-Employee Director Compensation Policy and will vest fully on either the first grant anniversary or the next annual stockholder meeting, whichever comes first.

When do Daniel Bradbury's June 2025 VANI stock options expire?

The non-qualified stock options granted to Daniel Bradbury on June 24, 2025, expire on June 23, 2035, giving them a 10-year term from the grant date.

What was the correction made to Bradbury's January 2025 VANI stock option grant?

The Form 4 disclosed a correction to Bradbury's January 1, 2025 stock option grant, adjusting the previously reported amount from 50,059 to 49,822 options (a reduction of 237 options) due to a clerical error. These options have an exercise price of $1.16.

What is the vesting schedule for VANI director Bradbury's January 2025 stock options?

The January 2025 stock options vest in four equal installments, with one-fourth vesting at the end of each calendar quarter following the grant date, subject to Bradbury's continued service through each vesting date.
Vivani Medical

NASDAQ:VANI

VANI Rankings

VANI Latest News

VANI Latest SEC Filings

VANI Stock Data

74.65M
30.19M
48.98%
8.41%
0.48%
Biotechnology
Electromedical & Electrotherapeutic Apparatus
Link
United States
ALAMEDA